Primary Myelofibrosis Market Outlook 2025 – In-Depth Data for Business Expansion to 2034

 Unlock 30% off global market reports with code ONLINE30 — get insights on tariff changes, macro trends, and global economic shifts.

 
 What is the current market size of the primary myelofibrosis industry, and what growth rate is it expected to achieve?
 The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing disease awareness among clinicians, rising use of jak inhibitors, growing diagnostic capabilities and genetic testing, increasing patient access to hematology specialists and rising clinical trial activity.
 
 The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing pipeline of novel therapies, increasing demand for disease-modifying treatments, rising prevalence in aging populations, growing emphasis on combination therapies and increasing investment from pharma and biotech firms. Major trends in the forecast period include advancements in targeted drug development, integration of next-generation sequencing (ngs) in diagnostics, technology-driven monitoring solutions, developments in combination therapy protocols and advancements in bone marrow fibrosis imaging techniques.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp
 
 What are the major drivers contributing to the growth of the primary myelofibrosis market?
 The increasing prevalence of myelofibrosis is expected to propel the growth of the primary myelofibrosis market going forward. Myelofibrosis refers to a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells, leading to extensive scarring in the bone marrow and resulting in severe anemia, weakness, fatigue, and an enlarged spleen. The increasing prevalence of myelofibrosis is primarily due to the aging population, as the condition most commonly affects individuals over the age of 60, and longer life expectancy is contributing to a higher number of diagnosed cases. The rising prevalence of myelofibrosis improves the management of primary myelofibrosis by driving research, enhancing early diagnosis, increasing treatment options, and promoting better clinical guidelines and specialized care. For instance, in November 2024, according to the report published by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the increasing prevalence of myelofibrosis is driving the growth of the primary myelofibrosis market.
 
 What are the major market segments driving the growth of the primary myelofibrosis industry?
 The primary myelofibrosis market covered in this report is segmented –
 
 1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types
 2) By Services: Treatment, Diagnosis
 3) By Dosage Forms: Solid, Liquids, Other Dosage Forms
 4) By Age: Adult, Child, Geriatric
 5) By End User: Hospitals, Clinics, Other End Users
 
 Subsegments:
 1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
 2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis
 3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders
 4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report
 
 How are emerging trends transforming the primary myelofibrosis market dynamics?
 Major companies operating in the primary myelofibrosis market are focusing on developing innovative products such as Janus kinase 2 inhibiting tablets to improve symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which is involved in the abnormal signaling pathways that cause excessive blood cell production in primary myelofibrosis. These tablets help reduce spleen size, alleviate fatigue and bone pain symptoms, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. It is approved by South Korea’s Ministry of Food and Drug Safety and intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.
 
 Who are the key market players contributing to the growth of the primary myelofibrosis industry?
 Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.
 
 Which regions are leading the growth of the primary myelofibrosis market globally?
 North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Primary Myelofibrosis Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24669
 
 Need Customized Data On Primary Myelofibrosis Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Americas +1 310–496-7795
 Asia +44 2071930708
 Europe +44 7882 955267
 Email us at info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company